FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014415900> ?p ?o ?g. }

• W2014415900 endingPage "467" @default.
• W2014415900 startingPage "460" @default.
• W2014415900 abstract "Purpose: To report results for 49 men with squamous cell carcinoma (SCC) of the penis treated with primary penile interstitial brachytherapy at one of two institutions: the Ottawa Regional Cancer Center, Ottawa, and the Princess Margaret Hospital, Toronto, Ontario, Canada. Methods and Materials: From September 1989 to September 2003, 49 men (mean age, 58 years; range, 22–93 years) had brachytherapy for penile SCC. Fifty-one percent of tumors were T1, 33% T2, and 8% T3; 4% were in situ and 4% Tx. Grade was well differentiated in 31%, moderate in 45%, and poor in 2%; grade was unspecified for 20%. One tumor was verrucous. All tumors in Toronto had pulsed dose rate (PDR) brachytherapy (n = 23), whereas those in Ottawa had either Iridium wire (n = 22) or seeds (n = 4). Four patients had a single plane implant with a plastic tube technique, and all others had a volume implant with predrilled acrylic templates and two or three parallel planes of needles (median, six needles). Mean needle spacing was 13.5 mm (range, 10–18 mm), mean dose rate was 65 cGy/h (range, 33–160 cGy/h), and mean duration was 98.8 h (range, 36–188 h). Dose rates for PDR brachytherapy were 50–61.2 cGy/h, with no correction in total dose, which was 60 Gy in all cases. Results: Median follow-up was 33.4 months (range, 4–140 months). At 5 years, actuarial overall survival was 78.3% and cause-specific survival 90.0%. Four men died of penile cancer, and 6 died of other causes with no evidence of recurrence. The cumulative incidence rate for never having experienced any type of failure at 5 years was 64.4% and for local failure was 85.3%. All 5 patients with local failure were successfully salvaged by surgery; 2 other men required penectomy for necrosis. The soft tissue necrosis rate was 16% and the urethral stenosis rate 12%. Of 8 men with regional failure, 5 were salvaged by lymph node dissection with or without external radiation. All 4 men with distant failure died of disease. Of 49 men, 42 had an intact and tumor-free penis at last follow-up or death. The actuarial penile preservation rate at 5 years was 86.5%. Conclusions: Brachytherapy is an effective treatment for T1, T2, and selected T3 SCC of the penis. Close follow-up is mandatory because local failures and many regional failures can be salvaged by surgery. Purpose: To report results for 49 men with squamous cell carcinoma (SCC) of the penis treated with primary penile interstitial brachytherapy at one of two institutions: the Ottawa Regional Cancer Center, Ottawa, and the Princess Margaret Hospital, Toronto, Ontario, Canada. Methods and Materials: From September 1989 to September 2003, 49 men (mean age, 58 years; range, 22–93 years) had brachytherapy for penile SCC. Fifty-one percent of tumors were T1, 33% T2, and 8% T3; 4% were in situ and 4% Tx. Grade was well differentiated in 31%, moderate in 45%, and poor in 2%; grade was unspecified for 20%. One tumor was verrucous. All tumors in Toronto had pulsed dose rate (PDR) brachytherapy (n = 23), whereas those in Ottawa had either Iridium wire (n = 22) or seeds (n = 4). Four patients had a single plane implant with a plastic tube technique, and all others had a volume implant with predrilled acrylic templates and two or three parallel planes of needles (median, six needles). Mean needle spacing was 13.5 mm (range, 10–18 mm), mean dose rate was 65 cGy/h (range, 33–160 cGy/h), and mean duration was 98.8 h (range, 36–188 h). Dose rates for PDR brachytherapy were 50–61.2 cGy/h, with no correction in total dose, which was 60 Gy in all cases. Results: Median follow-up was 33.4 months (range, 4–140 months). At 5 years, actuarial overall survival was 78.3% and cause-specific survival 90.0%. Four men died of penile cancer, and 6 died of other causes with no evidence of recurrence. The cumulative incidence rate for never having experienced any type of failure at 5 years was 64.4% and for local failure was 85.3%. All 5 patients with local failure were successfully salvaged by surgery; 2 other men required penectomy for necrosis. The soft tissue necrosis rate was 16% and the urethral stenosis rate 12%. Of 8 men with regional failure, 5 were salvaged by lymph node dissection with or without external radiation. All 4 men with distant failure died of disease. Of 49 men, 42 had an intact and tumor-free penis at last follow-up or death. The actuarial penile preservation rate at 5 years was 86.5%. Conclusions: Brachytherapy is an effective treatment for T1, T2, and selected T3 SCC of the penis. Close follow-up is mandatory because local failures and many regional failures can be salvaged by surgery." @default.
• W2014415900 created "2016-06-24" @default.
• W2014415900 creator A5021967618 @default.
• W2014415900 creator A5027439380 @default.
• W2014415900 creator A5042314400 @default.
• W2014415900 creator A5084148111 @default.
• W2014415900 creator A5087929642 @default.
• W2014415900 date "2005-06-01" @default.
• W2014415900 modified "2023-09-26" @default.
• W2014415900 title "Penile brachytherapy: Results for 49 patients" @default.
• W2014415900 cites W132229047 @default.
• W2014415900 cites W170878050 @default.
• W2014415900 cites W1965359675 @default.
• W2014415900 cites W1969203722 @default.
• W2014415900 cites W1969367663 @default.
• W2014415900 cites W1978864426 @default.
• W2014415900 cites W1981484813 @default.
• W2014415900 cites W1993261870 @default.
• W2014415900 cites W1996706019 @default.
• W2014415900 cites W2008649250 @default.
• W2014415900 cites W2012860500 @default.
• W2014415900 cites W2036432434 @default.
• W2014415900 cites W2036710159 @default.
• W2014415900 cites W2042489391 @default.
• W2014415900 cites W2085513176 @default.
• W2014415900 cites W2091725395 @default.
• W2014415900 cites W2094014005 @default.
• W2014415900 cites W2104832186 @default.
• W2014415900 cites W2104959058 @default.
• W2014415900 cites W2114601036 @default.
• W2014415900 cites W2120663358 @default.
• W2014415900 cites W2141507700 @default.
• W2014415900 cites W2142121892 @default.
• W2014415900 cites W2145998194 @default.
• W2014415900 cites W2147918277 @default.
• W2014415900 cites W2155318011 @default.
• W2014415900 cites W2189050988 @default.
• W2014415900 cites W2260922242 @default.
• W2014415900 cites W2352092003 @default.
• W2014415900 cites W2398965589 @default.
• W2014415900 cites W2418690010 @default.
• W2014415900 cites W4293241248 @default.
• W2014415900 cites W4376453784 @default.
• W2014415900 doi "https://doi.org/10.1016/j.ijrobp.2004.10.016" @default.
• W2014415900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15890588" @default.
• W2014415900 hasPublicationYear "2005" @default.
• W2014415900 type Work @default.
• W2014415900 sameAs 2014415900 @default.
• W2014415900 citedByCount "78" @default.
• W2014415900 countsByYear W20144159002012 @default.
• W2014415900 countsByYear W20144159002013 @default.
• W2014415900 countsByYear W20144159002014 @default.
• W2014415900 countsByYear W20144159002015 @default.
• W2014415900 countsByYear W20144159002016 @default.
• W2014415900 countsByYear W20144159002017 @default.
• W2014415900 countsByYear W20144159002018 @default.
• W2014415900 countsByYear W20144159002019 @default.
• W2014415900 countsByYear W20144159002020 @default.
• W2014415900 countsByYear W20144159002021 @default.
• W2014415900 countsByYear W20144159002022 @default.
• W2014415900 crossrefType "journal-article" @default.
• W2014415900 hasAuthorship W2014415900A5021967618 @default.
• W2014415900 hasAuthorship W2014415900A5027439380 @default.
• W2014415900 hasAuthorship W2014415900A5042314400 @default.
• W2014415900 hasAuthorship W2014415900A5084148111 @default.
• W2014415900 hasAuthorship W2014415900A5087929642 @default.
• W2014415900 hasConcept C141071460 @default.
• W2014415900 hasConcept C2777180808 @default.
• W2014415900 hasConcept C2777416452 @default.
• W2014415900 hasConcept C2777786686 @default.
• W2014415900 hasConcept C2781411149 @default.
• W2014415900 hasConcept C2989005 @default.
• W2014415900 hasConcept C509974204 @default.
• W2014415900 hasConcept C71924100 @default.
• W2014415900 hasConceptScore W2014415900C141071460 @default.
• W2014415900 hasConceptScore W2014415900C2777180808 @default.
• W2014415900 hasConceptScore W2014415900C2777416452 @default.
• W2014415900 hasConceptScore W2014415900C2777786686 @default.
• W2014415900 hasConceptScore W2014415900C2781411149 @default.
• W2014415900 hasConceptScore W2014415900C2989005 @default.
• W2014415900 hasConceptScore W2014415900C509974204 @default.
• W2014415900 hasConceptScore W2014415900C71924100 @default.
• W2014415900 hasIssue "2" @default.
• W2014415900 hasLocation W20144159001 @default.
• W2014415900 hasLocation W20144159002 @default.
• W2014415900 hasOpenAccess W2014415900 @default.
• W2014415900 hasPrimaryLocation W20144159001 @default.
• W2014415900 hasRelatedWork W1986062050 @default.
• W2014415900 hasRelatedWork W1988019440 @default.
• W2014415900 hasRelatedWork W2001080205 @default.
• W2014415900 hasRelatedWork W2006586614 @default.
• W2014415900 hasRelatedWork W2042472674 @default.
• W2014415900 hasRelatedWork W2102924433 @default.
• W2014415900 hasRelatedWork W2115056993 @default.
• W2014415900 hasRelatedWork W2162694846 @default.
• W2014415900 hasRelatedWork W2419126276 @default.
• W2014415900 hasRelatedWork W2917558093 @default.
• W2014415900 hasVolume "62" @default.

• next